Price Don’t Lie: Ultragenyx Pharmaceutical Inc’s Stock Is Buy After Today’s Big Increase

Price Don't Lie: Ultragenyx Pharmaceutical Inc's Stock Is Buy After Today's Big Increase

The stock of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) is a huge mover today! The stock increased 6.27% or $5.06 on November 23, hitting $85.81. About 572,702 shares traded hands. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) has risen 12.88% since April 22, 2016 and is uptrending. It has outperformed by 7.47% the S&P500.
The move comes after 8 months positive chart setup for the $3.34B company. It was reported on Nov, 24 by Barchart.com. We have $93.53 PT which if reached, will make NASDAQ:RARE worth $300.60M more.

Analysts await Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) to report earnings on February, 23. They expect $-1.74 earnings per share, down 22.54% or $0.32 from last year’s $-1.42 per share. After $-1.64 actual earnings per share reported by Ultragenyx Pharmaceutical Inc for the previous quarter, Wall Street now forecasts 6.10% negative EPS growth.

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) Ratings Coverage

Out of 13 analysts covering Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), 12 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 92% are positive. Ultragenyx Pharmaceutical Inc has been the topic of 21 analyst reports since July 27, 2015 according to StockzIntelligence Inc. The firm has “Outperform” rating given on Tuesday, May 10 by Wedbush. Stifel Nicolaus initiated Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) rating on Tuesday, December 1. Stifel Nicolaus has “Buy” rating and $125 price target. The firm earned “Sell” rating on Monday, November 14 by Citigroup. The stock of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) earned “Equal Weight” rating by Morgan Stanley on Monday, July 27. The rating was initiated by Credit Suisse on Thursday, January 21 with “Outperform”. On Tuesday, August 18 the stock rating was downgraded by Zacks to “Buy”. Raymond James initiated Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) on Tuesday, September 1 with “Outperform” rating. The rating was maintained by SunTrust on Monday, July 13 with “Buy”. As per Thursday, September 3, the company rating was initiated by Citigroup. Bank of America initiated Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) on Tuesday, June 28 with “Buy” rating.

According to Zacks Investment Research, “Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company’s product pipeline include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM which are in different clinical phases. Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California.”

Insitutional Activity: The institutional sentiment increased to 1.21 in 2016 Q2. Its up 0.24, from 0.97 in 2016Q1. The ratio is positive, as 19 funds sold all Ultragenyx Pharmaceutical Inc shares owned while 55 reduced positions. 19 funds bought stakes while 53 increased positions. They now own 36.54 million shares or 1.13% less from 36.95 million shares in 2016Q1.
Moreover, Pnc Fincl Services Grp has 0% invested in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) for 200 shares. Quantbot Lp has 7,391 shares for 0.04% of their US portfolio. American Int Gru Inc last reported 20,740 shares in the company. Tocqueville Asset Management L P, a New York-based fund reported 16,700 shares. Moreover, Jennison Assocs Ltd Liability Com has 0.03% invested in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) for 498,041 shares. Us Natl Bank De accumulated 0% or 693 shares. Bancorporation Of America Corp De, a North Carolina-based fund reported 36,955 shares. The Georgia-based Voya Mngmt Ltd Liability Corp has invested 0.02% in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE). The Delaware-based Blackrock Advisors Ltd Liability has invested 0.02% in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE). Moreover, Principal Grp Incorporated has 0% invested in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) for 66,892 shares. Geode Cap Mgmt Ltd Liability Corporation reported 263,221 shares or 0.01% of all its holdings. Rock Springs Capital Mngmt Ltd Partnership reported 141,500 shares or 0.51% of all its holdings. Columbia Partners L L C Investment Management holds 0.02% or 5,882 shares in its portfolio. Susquehanna Group Inc Llp reported 27,563 shares or 0% of all its holdings. Tcw Grp Inc Inc last reported 0.01% of its portfolio in the stock.

RARE Company Profile

Ultragenyx Pharmaceutical Inc., incorporated on June 13, 2011, is a clinical-stage biopharmaceutical company. The Firm is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Firm is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment. The Company’s pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment